Impact of the Definition of Peak Standardized Uptake Value on Quantification of Treatment Response
暂无分享,去创建一个
[1] H. Hoekstra,et al. [18F]FLT-PET in oncology: current status and opportunities , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[2] J. Nährig,et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Yuji Nakamoto,et al. Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[4] Adriaan A. Lammertsma,et al. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[5] Elisabeth Kjellén,et al. FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma , 2002, Head & neck.
[6] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[7] U. Haberkorn,et al. A new precursor for the radiosynthesis of [18F]FLT. , 2002, Nuclear medicine and biology.
[8] Michael E Phelps,et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. , 2006, Chest.
[9] J. Eary,et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Mattfeldt,et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[11] Falko Fend,et al. Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma , 2007, Clinical Cancer Research.
[12] R L Wahl,et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M Schwaiger,et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.
[14] Eric J. W. Visser,et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[15] Claude Nahmias,et al. Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors , 2008, Journal of Nuclear Medicine.
[16] Eric O. Aboagye,et al. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[17] J Nuyts,et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.
[18] Wei Chen,et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] W. Weber,et al. PET for response assessment in oncology: radiotherapy and chemotherapy , 2005 .
[20] Michael E. Phelps,et al. Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy , 2005, Molecular Imaging and Biology.
[21] A. Fischman,et al. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. , 2002, International journal of radiation oncology, biology, physics.
[22] M. Schwaiger,et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] T. Lehnert,et al. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET , 2007, Leukemia & lymphoma.
[24] R L Wahl,et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. , 1995, Radiology.
[25] R. Boellaard,et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] Wolfgang A Weber,et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. , 2007, The Lancet. Oncology.
[27] Torsten Mattfeldt,et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] H. Dittmann,et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[29] J. Yap,et al. Impact of variations in SUV methods for assessing cancer response using FDG-PET , 2011 .